Sign inJoin waitlistJoin the waitlist

RC

Richard Childs

Clincal Director, Senior Investigator, NHLBI · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Senior Investigator · Clinical Center at the National Institutes of Health
Present

Research

Compassionate Use of Remdesivir for Patients with Severe Covid-19
New England Journal of Medicine · 2020 · 1,870 citations
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
New England Journal of Medicine · 2000 · First of 12 authors · Corresponding · 797 citations
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Nature Medicine · 2007 · 654 citations

AB
Austin Barrett
56 papers
SL
Susan Leitman
28 papers
Cynthia Dunbar
22 papers
Ramaprasad Srinivasan
22 papers
NY
Neal Young
18 papers
BS
Bipin Savani
17 papers
David Stroncek
15 papers
Steven Pavletic
15 papers
Anthony Suffredini
14 papers
JT
John Tisdale
14 papers
MB
Minocher Battiwalla
13 papers
GA
Georg Aue
12 papers

Clinical trials

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
Principal investigator · Recruiting · Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2019–2028
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
Principal investigator · Active not recruiting · Phase 1
National Heart, Lung, and Blood Institute (NHLBI)
2018–2029
Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant
Principal investigator · Completed
National Heart, Lung, and Blood Institute (NHLBI)
2018–2022
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Principal investigator · Recruiting · Phase 1, Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2017–2032